Merck and partner Ridgeback Biotherapeutics said on Friday six lab studies showed that their experimental oral Covid-19 drug, molnupiravir, was active against the omicron variant, reports Reuters.
The data evaluated the antiviral activity of molnupiravir and other COVID-19 antiviral agents against COVID-19 variants of concern. Molnupiravir is yet to be studied against omicron in human studies, the companies said.
Molnupiravir and a rival oral pill from Pfizer Inc were authorised in the United States in December and are considered as important tools against omicron.
Pfizer said in December lab data suggested its drug Paxlovid retained its effectiveness against omicron.
Merck said earlier this month its pill has a mechanism that can work against omicron and any other variant.
Molnupiravir has been authorised for use in more than 10 countries, including the United States, United Kingdom and Japan.